Stock LOBE LOBE SCIENCES LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Lobe Sciences Ltd. Stock

Equities

LOBE

CA53946V2066

Pharmaceuticals

Market Closed - Canadian Securities Exchange
Other stock markets
 09:30:13 2024-05-28 am EDT 		5-day change 1st Jan Change
0.02 CAD +33.33% Intraday chart for Lobe Sciences Ltd. 0.00% -20.00%
Apr. 30 Lobe Sciences Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024 CI
Feb. 15 Lobe Sciences Ltd. Reports Earnings Results for the Full Year Ended August 31, 2023 CI

Financials

Sales 2022 - Sales 2023 841K 616K Capitalization 3.88M 2.84M
Net income 2022 -12M -8.79M Net income 2023 -4M -2.93M EV / Sales 2022 -
Net cash position 2022 933K 684K Net Debt 2023 112K 82.05K EV / Sales 2023 4.75 x
P/E ratio 2022
-0.29 x
P/E ratio 2023
-0.55 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 98.89%
More Fundamentals * Assessed data

Chart Lobe Sciences Ltd.

Dynamic Chart

Latest news about Lobe Sciences Ltd.

Lobe Sciences Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024 CI
Lobe Sciences Ltd. Reports Earnings Results for the Full Year Ended August 31, 2023 CI
Lobe Sciences Provides Update on L-130 Clinical Program MT
Lobe Sciences Ltd. Provides Update on L-130 Clinical Program CI
Lobe Sciences Provides Update on L-130 Oral Psilocin Compound MT
Lobe Sciences Appoints CFO MT
Lobe Sciences Ltd. Appoints Mathew Lee as Chief Financial Officer CI
Lobe Sciences Amends Terms of Altemia Share Purchase Agreement MT
Lobe Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023 CI
Lobe Sciences Ltd. Initiates Phase 1 Clinical Trial of L-130 CI
Lobe Sciences Appoints Baxter Phillips as Chief Operating Officer CI
Lobe Sciences Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023 CI
Lobe Sciences Ltd. completed the acquisition of Altemia and Company, LLC from Sancilio, LLC, PBHC1, LLC and Bruce Crawford for CAD 3.8 million. CI
Lobe Sciences Ltd. signed a share purchase agreement to acquire Altemia and Company, LLC for CAD 3.8 million. CI
Lobe Sciences Ltd. announced that it expects to receive $0.25 million in funding CI
More news

Press releases Lobe Sciences Ltd.

Lobe Sciences Ltd. and Clearway Global Announce Change of Control and Focus on Creating Value for Shareholders BU
Lobe Sciences Provides Company Review of 2023 BU
Lobe Sciences Provides Update on L-130 Clinical Program BU
Lobe Sciences Provides Update on L-130 Oral Psilocin Compound BU
Lobe Sciences : Corporate Presentation PU
More press releases

Quotes and Performance

1 day+33.33%
3 months+33.33%
6 months-20.00%
Current year-20.00%
More quotes

Highs and lows

1 week
0.02
Extreme 0.015
0.02
1 month
0.02
Extreme 0.015
0.03
Current year
0.02
Extreme 0.015
0.03
1 year
0.01
Extreme 0.01
0.03
3 years
0.01
Extreme 0.01
0.81
5 years
0.01
Extreme 0.01
1.80
10 years
0.01
Extreme 0.01
1.80
More quotes

Managers and Directors - Lobe Sciences Ltd.

Managers TitleAgeSince
Philip Young CEO
 Chief Executive Officer 66 21-01-14
Mathew Lee DFI
 Director of Finance/CFO 40 23-09-17
Maghsoud Dariani CTO
 Chief Tech/Sci/R&D Officer - 20-07-20
Members of the board TitleAgeSince
Philip Young CEO
 Chief Executive Officer 66 21-01-14
Baxter Phillips COO
 Chief Operating Officer 48 22-10-02
Michael Petter BRD
 Director/Board Member - 21-01-07
More insiders

Quotes

Date Price Change Volume
24-05-28 0.02 +33.33% 8,333

Delayed Quote Canadian Securities Exchange, May 28, 2024 at 09:30 am EDT

More quotes

Company Profile

Lobe Sciences Ltd. is a Canada-based biopharmaceutical company focused on developing patient-friendly, practical psychedelic medicines. The Company, through collaborations with partners, is engaged in drug research and development using sub-hallucinatory doses of proprietary compounds to treat Orphan diseases. Its new chemical entities, L-130 and L-131, are being developed to address unmet medical needs such as Chronic Cluster Headaches and other Orphan diseases. In addition, the Company is commercializing Altemia, for the treatment of patients diagnosed with Sickle Cell Disease. Its subsidiaries include Eleusian Biosciences Corp., Lobe Sciences Australia Pty Ltd. and Altemia & Company, LLC.
Sector
Pharmaceuticals
Calendar
2024-06-27 - Q3 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Alternative Medicine

1st Jan change Capi.
LOBE SCIENCES LTD. Stock Lobe Sciences Ltd.
-20.00% 1.89M
DONG-E-E-JIAO CO.,LTD. Stock Dong-E-E-Jiao Co.,Ltd.
+42.07% 6.28B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD. Stock Shijiazhuang Yiling Pharmaceutical Co., Ltd.
-21.20% 4.25B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED Stock Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
+5.38% 3.36B
TASLY PHARMACEUTICAL GROUP CO., LTD Stock Tasly Pharmaceutical Group Co., Ltd
-16.98% 2.96B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. Stock Shandong Buchang Pharmaceuticals Co., Ltd.
-5.82% 2.45B
HENAN LINGRUI PHARMACEUTICAL CO., LTD. Stock Henan Lingrui Pharmaceutical Co., Ltd.
+45.47% 1.97B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD. Stock GuangYuYuan Chinese Herbal Medicine Co., Ltd.
-12.67% 1.61B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD. Stock Tibet Cheezheng Tibetan Medicine Co., Ltd.
-3.91% 1.6B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD Stock Zhejiang Jolly Pharmaceutical Co.,LTD
+44.56% 1.51B
Alternative Medicine
  1. Stock Market
  2. Equities
  3. LOBE Stock